Researchers conducted a clinical trial involving 259 patients who were newly diagnosed with acute myeloid leukemia (AML). The study tested a specific treatment plan: a 7-day course of the drug venetoclax paired with different types of intensive chemotherapy.
The results showed that over 90% of patients achieved complete remission, and about 92% reached a state where minimal residual disease was not detected. These figures were observed during an 18-month follow-up period. The study also looked at survival rates and how quickly the body's blood counts recovered after treatment.
While the results are promising, it is important to note that because the study followed patients for only 18 months, the final median survival times were not yet reached. The shorter venetoclax schedule was intended to help manage certain risks associated with chemotherapy. Patients and families should discuss these findings with their oncology team to understand how this specific treatment approach fits into individual care plans.